Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, reaching a new high of 47.8 HKD, driven by a strategic partnership with PT DIASTIKA BIOTEKINDO for cancer diagnostics in Indonesia [1][2] Group 1: Partnership and Market Expansion - The company has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on molecular diagnostic testing and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1][2] - This partnership allows the company to leverage PT DIASTIKA BIOTEKINDO's existing channels to enter the Indonesian market with blood-based microRNA or multi-omics cancer detection devices [2] - The collaboration aims to utilize local policies in Indonesia, such as tax incentives for local content, and regulatory flexibility under ASEAN medical device frameworks to facilitate market entry [2] Group 2: Regional and Global Strategy - Indonesia is positioned as a pilot region for the company's operations, with plans to replicate the business model in Southeast Asia, the Middle East, North Africa, and other regions that share similar cancer profiles and healthcare structures [2]

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, rising over 8% to reach a new high of 47.8 HKD, following the announcement of a memorandum of understanding with PT DIASTIKA BIOTEKINDO for collaboration in the Indonesian market [1][2] Group 1 - The company’s indirect wholly-owned subsidiary, MiRXES PTE. LTD., has entered into a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on molecular diagnostic testing and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1][2] - The memorandum is valid for 12 months from the date of signing [1] - Through this partnership, the company aims to leverage PT DIASTIKA BIOTEKINDO's existing channels to deploy blood-based microRNA or multi-omics cancer detection devices in the Indonesian market [2] Group 2 - The collaboration will allow the company to benefit from Indonesia's localization policies, such as tax incentives for local content rates of 40% [2] - The partnership is expected to provide regulatory flexibility under the ASEAN-centered medical device framework [2] - Indonesia is viewed as a pilot region for the company to replicate its business model in Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare structures [2]

MIRXES-B(02629)涨超8%，盘中高见47.8港元创上市新高。截至发稿，涨7.28%，报47.38港元，成交额 1413.42万港元。 消息面上，8月15日，MIRXES-B发布公告，公司的间接全资附属公司MiRXES PTE.LTD.近期已与PT DIASTIKA BIOTEKINDO(一间于印尼证券交易所上市的公司，股份代号：CHEK)(PT DIASTIKA BIOTEKINDO)订立一份谅解备忘录，据此，双方同意在印尼进行用于高发病率及高死亡率癌症早期检 测及诊断的分子诊断检测及相关仪器的注册及商业化方面进行合作。谅解备忘录期限自签署日期起计 (包括该日)为期12个月。 公告称，透过与PT DIASTIKA BIOTEKINDO合作，该集团可：透过PT DIASTIKA BIOTEKINDO现有 渠道即时透过部署基于血液的microRNA或多组学高发病率癌症(如胃癌、肺癌等)检测设备方式进军印 尼市场；利用印尼推行本地化政策(如因本地化率40%享受税务优惠)及以东盟为中心的医疗器械框架实 现监管灵活性；及利用印尼作为示范性开业地区将业务复制至东南亚、中东、北非及其他地区(该等地 区均有相似癌 ...

Core Viewpoint - MiRXES-B (02629) has entered into a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on the registration and commercialization of molecular diagnostic tests and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1] Group 1 - The memorandum is valid for 12 months from the date of signing [1] - The collaboration allows MiRXES to leverage PT DIASTIKA BIOTEKINDO's existing channels to enter the Indonesian market with blood-based microRNA or multi-omics cancer detection devices for prevalent cancers such as gastric and lung cancer [1] - The partnership aims to utilize local policies in Indonesia, such as tax incentives for a localization rate of 40%, and regulatory flexibility under ASEAN-centered medical device frameworks [1] Group 2 - Indonesia is viewed as a pilot region for the business, with plans to replicate operations in Southeast Asia, the Middle East, North Africa, and other regions that have similar cancer profiles and healthcare structures [1]

Group 1 - The company MiRXES-B (02629) has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO for collaboration in molecular diagnostic testing and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1] - The memorandum is valid for 12 months from the date of signing [1] - The collaboration allows the company to leverage PT DIASTIKA BIOTEKINDO's existing channels to enter the Indonesian market with blood-based microRNA or multi-omics testing devices for high-incidence cancers such as gastric and lung cancer [1] Group 2 - The partnership enables the company to benefit from local policies in Indonesia, such as tax incentives for localization rates of 40% [1] - The collaboration aims to achieve regulatory flexibility under the ASEAN-centered medical device framework [1] - Indonesia is positioned as a pilot region for the company to replicate its business model in Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare structures [1]

Core Viewpoint - Company MiRXES-B has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on the registration and commercialization of molecular diagnostic tests for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1][2] Group 1: Collaboration Details - The memorandum is valid for 12 months and includes activities such as sales and distribution of new blood-based microRNA and multi-omics cancer early detection products in Indonesia [1] - The collaboration will involve joint development and clinical validation of projects for the registration of diagnostic devices, as well as training activities for Indonesian scientists and laboratory users [1] - The partnership will explore local manufacturing opportunities [1] Group 2: Market Potential and Strategy - PT DIASTIKA BIOTEKINDO operates a network of over 300 hospitals in Indonesia, providing immediate scale benefits for medical services, with 70% of these hospitals located in Java, serving 57% of the Indonesian population [2] - The collaboration allows the company to leverage existing distribution channels to enter the Indonesian market with blood-based cancer detection devices [2] - The partnership aims to utilize Indonesia's localization policies for tax incentives and regulatory flexibility, with plans to replicate the business model in Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare structures [2]